JP2021177761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021177761A5 JP2021177761A5 JP2021112234A JP2021112234A JP2021177761A5 JP 2021177761 A5 JP2021177761 A5 JP 2021177761A5 JP 2021112234 A JP2021112234 A JP 2021112234A JP 2021112234 A JP2021112234 A JP 2021112234A JP 2021177761 A5 JP2021177761 A5 JP 2021177761A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- cell carcinoma
- renal cell
- gene
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29403810P | 2010-01-11 | 2010-01-11 | |
| US61/294,038 | 2010-01-11 | ||
| US34623010P | 2010-05-19 | 2010-05-19 | |
| US61/346,230 | 2010-05-19 | ||
| JP2019114273A JP7307602B2 (ja) | 2010-01-11 | 2019-06-20 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019114273A Division JP7307602B2 (ja) | 2010-01-11 | 2019-06-20 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021177761A JP2021177761A (ja) | 2021-11-18 |
| JP2021177761A5 true JP2021177761A5 (https=) | 2022-03-16 |
| JP7385630B2 JP7385630B2 (ja) | 2023-11-22 |
Family
ID=44258831
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548188A Active JP6286124B2 (ja) | 2010-01-11 | 2011-01-07 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2016041689A Pending JP2016174600A (ja) | 2010-01-11 | 2016-03-04 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2017080314A Active JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2019114273A Active JP7307602B2 (ja) | 2010-01-11 | 2019-06-20 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2021112234A Active JP7385630B2 (ja) | 2010-01-11 | 2021-07-06 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548188A Active JP6286124B2 (ja) | 2010-01-11 | 2011-01-07 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2016041689A Pending JP2016174600A (ja) | 2010-01-11 | 2016-03-04 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2017080314A Active JP6546214B2 (ja) | 2010-01-11 | 2017-04-14 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
| JP2019114273A Active JP7307602B2 (ja) | 2010-01-11 | 2019-06-20 | 遺伝子発現を用いて腎癌の臨床的結果の見込みを判定する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9551034B2 (https=) |
| EP (5) | EP3178944B1 (https=) |
| JP (5) | JP6286124B2 (https=) |
| AU (1) | AU2011203977B2 (https=) |
| CA (3) | CA3128103C (https=) |
| DK (1) | DK3178944T3 (https=) |
| ES (2) | ES2741379T3 (https=) |
| IL (6) | IL219978A (https=) |
| MX (3) | MX341866B (https=) |
| NZ (4) | NZ617003A (https=) |
| SG (1) | SG181806A1 (https=) |
| WO (1) | WO2011085263A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3178944B1 (en) | 2010-01-11 | 2019-05-15 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| SG187045A1 (en) | 2010-08-13 | 2013-02-28 | Somalogic Inc | Pancreatic cancer biomarkers and uses thereof |
| WO2013016673A2 (en) * | 2011-07-27 | 2013-01-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma |
| EP2748356A2 (en) * | 2011-08-22 | 2014-07-02 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
| HK1212389A1 (en) | 2011-10-24 | 2016-06-10 | Signalchem Lifesciences Corporation | Carbonic anhydrase ix-related markers and use thereof |
| US8725426B2 (en) | 2012-01-31 | 2014-05-13 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| JP2016521979A (ja) * | 2013-05-30 | 2016-07-28 | ジェノミック ヘルス， インコーポレイテッド | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム |
| SG11201602019XA (en) * | 2013-09-17 | 2016-04-28 | Agency Science Tech & Res | Multigene assay for prognosis of renal cancer |
| WO2016034611A1 (en) * | 2014-09-02 | 2016-03-10 | Max-Delbrück-Centrum für Molekulare Medizin | Antisense oligonucleotides targeting 3'utr region of a20 |
| JP6638128B2 (ja) * | 2014-10-30 | 2020-01-29 | 公立大学法人福島県立医科大学 | 腎がんの悪性度の検査マーカー及び検査方法 |
| WO2016126883A1 (en) * | 2015-02-03 | 2016-08-11 | Cedars-Sinai Medical Center | Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer |
| GB201616912D0 (en) | 2016-10-05 | 2016-11-16 | University Of East Anglia | Classification of cancer |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| WO2018161027A1 (en) * | 2017-03-03 | 2018-09-07 | Oregon State University | Antisense antibacterial compounds and methods |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| US11335464B2 (en) * | 2018-01-12 | 2022-05-17 | Siemens Medical Solutions Usa, Inc. | Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making |
| CA3105292A1 (en) * | 2018-08-10 | 2020-02-13 | Omniseq, Inc. | Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade |
| WO2020085936A1 (ru) * | 2018-10-24 | 2020-04-30 | Общество С Ограниченной Ответственностью "Онкобокс" | Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки |
| US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
| JP2022523301A (ja) | 2019-01-23 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンジオポエチン様７（ａｎｇｐｔｌ７）阻害剤による眼疾患の治療 |
| WO2021030604A1 (en) * | 2019-08-14 | 2021-02-18 | University Of Massachusetts | Urinary rna signatures in renal cell carcinoma (rcc) |
| WO2022182768A1 (en) | 2021-02-26 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
| CN113025716A (zh) * | 2021-03-02 | 2021-06-25 | 北京大学第一医院 | 一种用于人肿瘤分级的基因组合及其用途 |
| CN113817816A (zh) * | 2021-10-08 | 2021-12-21 | 济南艾迪康医学检验中心有限公司 | 检测epas1基因突变的引物、试剂盒和方法 |
| WO2023080900A1 (en) * | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| CN118711678B (zh) * | 2024-08-22 | 2025-12-12 | 暨南大学附属第一医院（广州华侨医院） | 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US7135314B1 (en) * | 1997-04-17 | 2006-11-14 | Cell Therapeutics, Inc. | Human phosphatidic acid phosphatase |
| CA2397207C (en) * | 2000-01-13 | 2013-12-03 | Genentech, Inc. | Novel stra6 polypeptides |
| DE10126344A1 (de) * | 2000-07-14 | 2002-01-24 | Max Planck Gesellschaft | Apoptose-induzierende DNA-Sequenzen |
| WO2002027028A1 (en) * | 2000-09-28 | 2002-04-04 | Atairgin Technologies, Inc. | A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes |
| US20030109434A1 (en) * | 2001-03-19 | 2003-06-12 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of kidney cancer |
| CA2442820A1 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
| JP2005500832A (ja) * | 2001-06-18 | 2005-01-13 | ロゼッタ・インファーマティクス・インコーポレーテッド | 乳癌患者の診断および予後 |
| US7470509B2 (en) | 2002-02-08 | 2008-12-30 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer |
| CA2992643C (en) | 2002-03-13 | 2019-06-18 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| AU2003288918A1 (en) * | 2002-10-04 | 2004-05-04 | Van Andel Research Institute | Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers |
| AU2003298689A1 (en) | 2002-11-21 | 2004-06-18 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| WO2004097052A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for prognosis and treatment of solid tumors |
| ES2609234T3 (es) | 2003-06-24 | 2017-04-19 | Genomic Health, Inc. | Predicción de la probabilidad de recidiva de cáncer |
| EP1644522A2 (en) | 2003-07-02 | 2006-04-12 | Novartis AG | Genes regulated in ovarian cancer as prognostic and therapeutic targets |
| US20050002904A1 (en) * | 2003-07-03 | 2005-01-06 | Wary Kishore K. | Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP) |
| US7526387B2 (en) | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| WO2005024603A2 (en) | 2003-09-10 | 2005-03-17 | The Board Of Regents Of The University Of Texas System | Methods for detecting, diagnosing and treating human renal cell carcinoma |
| JP2005211023A (ja) * | 2004-01-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | 腎細胞癌の転移若しくは再発の可能性を予測する方法 |
| US20070224596A1 (en) * | 2004-04-09 | 2007-09-27 | Mariana Nacht | Compositions and methods for the modifying hypoxia induced gene regulation |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| WO2005117943A2 (en) * | 2004-05-27 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Biomarkers for monitoring inhibition of impdh pathway |
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| US20080119367A1 (en) * | 2004-12-17 | 2008-05-22 | Mayo Foundation For Medical Education And Research | Prognosis of Renal Cell Carcinoma |
| US20090258002A1 (en) | 2005-02-01 | 2009-10-15 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Biomarkers for Tissue Status |
| CN101120255A (zh) | 2005-02-18 | 2008-02-06 | 惠氏公司 | 用于实体肿瘤预后的药物基因组学标志 |
| WO2006124022A1 (en) * | 2005-05-13 | 2006-11-23 | Vanandel Research Institute | Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma |
| US20090186024A1 (en) | 2005-05-13 | 2009-07-23 | Nevins Joseph R | Gene Expression Signatures for Oncogenic Pathway Deregulation |
| US20070037186A1 (en) * | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| CA2611728A1 (en) * | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2006135886A2 (en) * | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1907858A4 (en) * | 2005-06-13 | 2009-04-08 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| DE602006012042D1 (de) * | 2005-06-15 | 2010-03-18 | Pfizer Ltd | Substituierte arylpyrazole zur verwendung gegen parasiten |
| KR101446626B1 (ko) * | 2005-09-02 | 2014-10-06 | 도레이 카부시키가이샤 | 신장암 진단, 신장암 환자 예후 예측을 위한 조성물 및 방법 |
| CN101292046B (zh) | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
| EP2332984A3 (en) * | 2005-09-30 | 2011-10-12 | Universiteit Maastricht | Tumor angiogenesis associated genes and a method for their identification |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| CN101365806B (zh) | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
| US20070141066A1 (en) | 2005-12-16 | 2007-06-21 | Genentech, Inc. | Method for Diagnosing, Prognosing and Treating Glioma |
| WO2007146668A2 (en) * | 2006-06-06 | 2007-12-21 | University Of Massachusetts | Use of imp3 as a prognostic marker for cancer |
| EP2046973A4 (en) * | 2006-08-10 | 2010-04-07 | Millennium Pharm Inc | IDENTIFICATION, ASSESSMENT AND TREATMENT OF CANCER THERAPY PATIENTS |
| WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
| WO2008083098A1 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Agents for reversing epigenetic silencing of genes |
| US20080286273A1 (en) | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
| EP1990417A1 (en) | 2007-05-11 | 2008-11-12 | Universität Bayreuth | Archaeal plasmid vector system |
| WO2009105640A1 (en) | 2008-02-22 | 2009-08-27 | Virginia Commonwealth University | Signatures associated with rejection or recurrence of cancer |
| WO2010056374A2 (en) | 2008-11-17 | 2010-05-20 | Veracyte, Inc. | Methods and compositions of molecular profiling for disease diagnostics |
| US20120142553A1 (en) * | 2009-06-26 | 2012-06-07 | Franciscus Petrus Smit | Molecular Markers in Kidney Cancer |
| CA3043089A1 (en) | 2009-11-23 | 2011-05-26 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
| EP3178944B1 (en) | 2010-01-11 | 2019-05-15 | Genomic Health, Inc. | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| EP2721179A4 (en) | 2011-06-16 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | BIOMARKER COMPOSITIONS AND METHOD THEREFOR |
| EP2748356A2 (en) | 2011-08-22 | 2014-07-02 | Somalogic, Inc. | Renal cell carcinoma biomarkers and uses thereof |
-
2011
- 2011-01-07 EP EP17153152.8A patent/EP3178944B1/en active Active
- 2011-01-07 CA CA3128103A patent/CA3128103C/en active Active
- 2011-01-07 EP EP19173150.4A patent/EP3561078A1/en not_active Withdrawn
- 2011-01-07 NZ NZ61700311A patent/NZ617003A/en unknown
- 2011-01-07 MX MX2012007882A patent/MX341866B/es active IP Right Grant
- 2011-01-07 MX MX2016010666A patent/MX375138B/es unknown
- 2011-01-07 WO PCT/US2011/020596 patent/WO2011085263A2/en not_active Ceased
- 2011-01-07 EP EP20210111.9A patent/EP3831964B1/en active Active
- 2011-01-07 CA CA3256492A patent/CA3256492A1/en active Pending
- 2011-01-07 AU AU2011203977A patent/AU2011203977B2/en active Active
- 2011-01-07 CA CA2783858A patent/CA2783858C/en active Active
- 2011-01-07 SG SG2012045142A patent/SG181806A1/en unknown
- 2011-01-07 EP EP15203193.6A patent/EP3029155A3/en not_active Withdrawn
- 2011-01-07 DK DK17153152.8T patent/DK3178944T3/da active
- 2011-01-07 NZ NZ600268A patent/NZ600268A/en unknown
- 2011-01-07 US US12/987,023 patent/US9551034B2/en active Active
- 2011-01-07 NZ NZ719474A patent/NZ719474A/en unknown
- 2011-01-07 ES ES17153152T patent/ES2741379T3/es active Active
- 2011-01-07 JP JP2012548188A patent/JP6286124B2/ja active Active
- 2011-01-07 NZ NZ705645A patent/NZ705645A/en unknown
- 2011-01-07 EP EP11732245.3A patent/EP2524055A4/en not_active Withdrawn
- 2011-01-07 ES ES20210111T patent/ES3027507T3/es active Active
-
2012
- 2012-05-24 IL IL219978A patent/IL219978A/en active IP Right Grant
- 2012-07-05 MX MX2020009704A patent/MX2020009704A/es unknown
-
2016
- 2016-03-04 JP JP2016041689A patent/JP2016174600A/ja active Pending
- 2016-12-05 US US15/368,979 patent/US10892038B2/en active Active
-
2017
- 2017-04-06 IL IL251635A patent/IL251635B/en active IP Right Grant
- 2017-04-14 JP JP2017080314A patent/JP6546214B2/ja active Active
- 2017-12-14 IL IL256335A patent/IL256335B/en active IP Right Grant
-
2018
- 2018-10-03 IL IL26210018A patent/IL262100B/en active IP Right Grant
-
2019
- 2019-06-20 JP JP2019114273A patent/JP7307602B2/ja active Active
- 2019-10-24 IL IL270151A patent/IL270151B/en active IP Right Grant
-
2020
- 2020-11-19 US US16/952,566 patent/US11776664B2/en active Active
-
2021
- 2021-02-07 IL IL280689A patent/IL280689B/en unknown
- 2021-07-06 JP JP2021112234A patent/JP7385630B2/ja active Active
-
2023
- 2023-08-23 US US18/454,312 patent/US12412642B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021177761A5 (https=) | ||
| Spruessel et al. | Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision | |
| Lu et al. | Circulating exosome‐derived bona fide long non‐coding RNAs predicting the occurrence and metastasis of hepatocellular carcinoma | |
| JP2019162150A5 (https=) | ||
| Fu et al. | Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer | |
| Yaman Agaoglu et al. | Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer | |
| Liu et al. | Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer | |
| Su et al. | Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection | |
| Selth et al. | Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease | |
| Wilting et al. | Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis | |
| Kaur et al. | S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia | |
| Chen et al. | Circulating microRNA-182 in plasma and its potential diagnostic and prognostic value for pancreatic cancer | |
| Sapre et al. | Circulating microRNAs as biomarkers of prostate cancer: the state of play | |
| Zhang et al. | Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis | |
| Li et al. | Genetic Heterogeneity of Breast Cancer Metastasis May Be Related to miR‐21 Regulation of TIMP‐3 in Translation | |
| CN104755627A (zh) | 用于肝样本的分类和局灶性结节不典型增生、肝细胞腺瘤和肝细胞癌的诊断的新方法 | |
| Li et al. | Overexpression of metastasis-associated protein 1 is significantly correlated with tumor angiogenesis and poor survival in patients with early-stage non-small cell lung cancer | |
| Lahat et al. | Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes | |
| Balacescu et al. | MicroRNAs role in prostate cancer | |
| WO2025112150A1 (zh) | 基于血清蛋白的乳腺肿瘤筛查的标志物及应用 | |
| CN115820860A (zh) | 基于增强子甲基化差异的非小细胞肺癌标志物筛选方法及其标志物和应用 | |
| Bayat et al. | Two long non‐coding RNAs, Prcat17. 3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer | |
| Shan et al. | [Retracted] Identification of Nine M6A‐Related Long Noncoding RNAs as Prognostic Signatures Associated with Oxidative Stress in Oral Cancer Based on Data from The Cancer Genome Atlas | |
| Cazares et al. | Molecular pathology of prostate cancer | |
| Cheong et al. | Large metastatic lymph node size, especially more than 2 cm: independent predictor of poor prognosis in node-positive gastric carcinoma |